Adiponectin and Insulin Resistance in Diabetic Nephropathy

Adiponectin is Positively Associated With Insulin Resistance in Subjects With Type 2 Diabetic Nephropathy and Effects by Angiotensin Type 1 Receptor Blocker Losartan

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00774904

Enrollment

Registered

2008-10-17

Start date

2007-04-30

Completion date

2007-11-30

Last updated

2008-10-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Nephropathy

Keywords

Type 2 Diabetes, Diabetic Nephropathy, Glucose Metabolism, Angiotensin II Type 1 Receptor Blockers

Brief summary

Plasma adiponectin concentration is inversely associated with renal function. There is little literature on adiponectin levels and regulation by antihypertensive medication with an angiotensin II-receptor blocker (ARB), especially in subjects with type 2 diabetes in different stage of chronic kidney disease (CKD).

Interventions

DRUGLosartan

Angiotensin II Type 1 Receptor Blockers

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Type 2 diabetic nephropathy * CKD at stage 1\ 4

Exclusion criteria

* Type 1 diabetes or nondiabetic renal disease * An elevated plasma K level.

Design outcomes

Primary

Measure	Time frame
GFR, HbA1c and the adiponectin concentration	6 month

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026